Letter to the editorAzithromycin therapy during respiratory syncytial virus bronchiolitis: Upper airway microbiome alterations and subsequent recurrent wheeze
References (9)
- et al.
Determinants of asthma after severe respiratory syncytial virus bronchiolitis
J Allergy Clin Immunol
(2012) - et al.
Randomized trial to evaluate azithromycin's effects on serum and upper airway IL-8 levels and recurrent wheezing in infants with respiratory syncytial virus bronchiolitis
J Allergy Clin Immunol
(2015) - et al.
Chronic macrolide therapy in inflammatory airways diseases
Chest
(2010) - et al.
The infant nasopharyngeal microbiome impacts severity of lower respiratory infection and risk of asthma development
Cell Host Microbe
(2015)
Cited by (0)
This study was supported by the Washington University Institute of Clinical and Translational Sciences (grant no. UL1 TR000448 from the National Center for Advancing Translational Sciences-subaward KL2 TR000450, RO1 HL61895, and RO1 HL092486) and the Children's Discovery Institute of Washington University and St Louis Children's Hospital. This was also supported in part (REDCap data base) by the Clinical and Translational Science Awards (CTSA) (grant no. UL1 TR000448), Siteman Comprehensive Cancer Center and the National Cancer Institute Cancer Center (grant no. P30 CA091842), and NIH/NHLBI R01HL130876.
Disclosure of potential conflict of interest: L. B. Bacharier reports grants from the National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI) AsthmaNet during the conduct of the study and personal fees from Aerocrine, GlaxoSmithKline, Genentech/Novartis, Merck Schering, Cephalon, DBV Technologies, Teva, Boehringer-Ingelheim, AstraZeneca, WebMD, and Sanofi outside the submitted work. M. Castro reports grants from the NIH during the conduct of the study; personal fees from Asthmatx/Boston Scientific, IPS/Holaria, Genentech, Merck, GSK, Genentech, Boehringer-Ingelheim, and Elsevier; grants from Boston Scientific, Amgen, Ception/Cephalon/Teva, Genetech, Medimmune, Merck, Novartis, GSK, Sanofi-Aventis, Vectura, NextBio, and KalaBios; and stock options from Sparo, Inc, all outside the submitted work. A. Beigelman reports grants from the NHLBI/National Institute of Allergy and Infectious Diseases/NIH AsthmaNet/ICAC. The rest of the authors declare that they have no relevant conflicts of interest.